Cervical Dysplasia Market Emerging Demands, Size & Revenue, Business Prospects to 2027
Cervical Dysplasia Market |
When there is precancerous or
aberrant cell proliferation in or around the cervix, it is called cervical
dysplasia. If detected too late, the presence could result in cervical cancer.
Cervical dysplasia has several main causes, one of which is the Human
Papillomavirus (HPV). One of the main drivers of the cervical dysplasia market
is the increase in government-funded cancer screening programmes. For instance,
the first government campaign to raise awareness of cervical dysplasia
screening using smear tests was introduced by Public Health England in March
2019. According to the same source, due to the stigma and fear surrounding the
Pap test, the percentage of women aged 25 and older who get smear tests is
currently at its lowest point in two decades.
One of the main drivers of the Cervical
Dysplasia Market is the increased incidence of cancer. According to a WHO
research, an estimated 5, 70,000 new cases are expected to be detected globally
year 2018. Around the world, 3,11,000 deaths were reported in 2018. The paper
also notes that this condition is the most prevalent malignancy in women linked
to HPV. As a result, it is projected that an increase in illness prevalence
will improve the screening of lesions brought on by the disease in the near
future.
The market for cervical dysplasia
is expected to rise over the forecast period due to an increase in awareness
efforts for the early detection of the illness. As an illustration, in 2019 the
U.S. January has been designated as Cervical Awareness Month by Congress. The
National Cervical Cancer Coalition emphasises numerous cervical cancer-related
topics throughout January while also emphasising the value of early diagnosis.
Therefore, during the projected period, a rise in government activities to
raise awareness about the disease's screening are anticipated to spur expansion
for Cervical Dysplasia
Market.
One of the primary diagnostic
tools for the diagnosis of cervical dysplasia is the colposcope. In the near
future, rising strategic initiatives done by key market players are anticipated
to fuel the growth of the diagnostic devices segment. For instance, in order to
support the National Screening Programme in Turkey, DYSIS Medical Ltd. and ITEM
Medical Technologies signed into a contract in March 2016. The Turkish Ministry
of Health received Colposcope devices from DYSIS Medical Ltd. for the purpose
of cervical cancer screening. As a result, expanding activities of this kind
are anticipated to improve the use of diagnostic tools in the near future.
Comments
Post a Comment